NEWS - 15 July, 2025 - Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, is pleased to announce that it has been selected for the third round of the Ministry of Economy, Trade and Industry (METI) and the New Energy and Industrial Technology Development Organization (NEDO)’s Generative AI Accelerator Challenge (GENIAC) project, which aims to strengthen domestic development capabilities in generative AI. Th

SUZHOU, China, July 14, 2025 /PRNewswire/ -- Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through its advanced AI and molecular dynamics(MD) platform. This powerful platform recently supported the successful design of BGM1812, a novel dual AMY3R/CTR receptor agonist for obesity treatment, as published in the July 2025 issue of the Journal of Medicinal Chemistry. This achievement underscores Divamics' consistent ability

BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient w

Goode Health is one of the only global supplements with RCT-backed longevity data, and it surpasses olive oil, green tea, and many others in impact COLUMBUS, Ohio, July 14, 2025 /PRNewswire/ -- In a groundbreaking clinical study published in Physiological Reports, researchers have found that Goode Health's Chocolate Superfood Beverage delivers statistically significant improvements across three core biological systems tied to aging, placing it in a rare class of scientifically validated nutritio

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the presentation of preclinical data on MAR002, a novel growth hormone receptor (GHR) antagonist antibody for the treatment of acromegaly, at the 2025 Annual Meeting of the Endocrine Society (ENDO). The oral presentation, titled “Developmen

– New Data from PURPOSE Trials Further Demonstrate that Lenacapavir (Yeztugo ® ) was Effective and Well Tolerated Across a Broad Range of Populations, Including Pregnant and Lactating Women, Adolescents and Young People – – Data Also Showed Twice-Yearly Injectable PrEP was Preferred vs. Daily Oral Medication Among PURPOSE Trial Participants – – Gilead’s Research Presentations and Community Events at IAS Reflect Commitment to Partnerships in Developing Person-Centered Options for a Diverse Range

LOS ANGELES, CA, USA I July 14, 2025 I Turn Therapeutics today announced the initiation of a randomized, double-blind, vehicle-controlled clinical trial evaluating its topical GX-03 formulation — previously used in the company’s advanced wound care product Hexagen — for the treatment of moderate-to-severe eczema (atopic dermatitis). Patient dosing commenced on July 11 in Dallas. Designed to support new drug approval, this clinical trial builds on in-vivo confirmation of the formulation’s potent

In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally RAHWAY, NJ, USA I July 14, 2025 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse transcriptase translocation inhibitor (NRTTI) for HIV pre-exposure prophylaxis (PrEP). The

First patient dosing in Company’s Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline results are expected in Q1 2026 Prior Phase 1b/2a efficacy findings demonstrated complete bacterial clearance in 14.3% of patients after just 10 days of treatment Feedback from U.S. Food and Drug Administration (FDA) anticipated in H2 2025, regarding plans to evaluate investigation and use of real-world e

ATLANTA, July 14, 2025 /PRNewswire/ -- In response to changes in the federal funding environment, the Arthritis Foundation and the Childhood Arthritis and Rheumatology Research Alliance (CARRA) have increased funding for their joint grant program that supports physician-led research in pediatric rheumatology. This year, the CARRA-Arthritis Foundation Grant Program will award nearly $2 million – an increase of $200,000 from the previous year – to advance research in this critical field. In light